Szewczyk to lead company’s commercial processes, business development and partnership strategies

Mark Szewczyk
Chief Commercial Officer

Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced that it has appointed healthcare and molecular diagnostics veteran and former Abbott executive Mark Szewczyk as Chief Commercial Officer. The addition of Szewczyk is the latest in a series of strategic appointments bolstering Strata Oncology’s commercial team, following the appointment of Trey Regalo as Vice President of Sales and Rob Manor as Vice President of Commercial Partnerships. 

“We are thrilled to welcome Mark to Strata Oncology. Successful cancer management requires collaboration, and nobody understands that better than Mark, who has decades of experience in leading teams that deliver exceptional results,” said Dan Rhodes, Ph.D., co-founder and Chief Executive Officer, Strata Oncology. “His proven leadership in commercial strategy and extensive experience in molecular diagnostics will be vital to our efforts to bring the right treatment to patients with cancer through precision medicine.”

Szewczyk brings more than 25 years of experience in healthcare and commercial leadership in molecular diagnostics. Prior to joining Strata Oncology, he served as Vice President, Global Commercial Operations, molecular diagnostics at Abbott; General Manager in Abbott’s molecular diagnostics division; General Manager, diagnostics imaging systems at Philips Healthcare; and General Manager of the Cleveland Clinic Home Care. Szewczyk holds a Masters of Business Administration from Drexel University and a Bachelor of Science in pharmacy from the Ohio State University.

“Strata Oncology is poised for significant growth and I am very excited to bring my experience in transforming healthcare organizations to the company,” said Szewczyk. “The team’s passion for changing the landscape of cancer care is clear and I look forward to working with these talented individuals to improve outcomes for patients with cancer.”